Ovid Therapeutics Inc. Common Stock OVID
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T00:48:41.559Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:01.398829374Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T00:44:59.353292+00:00
Ovid Therapeutics Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 1.95 | 508.5% | 43.4% | |||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | 2.62 | 243.6% | 19.0% | |||
| 40Δ | 2.81 | 239.4% | 17.5% | |||
| 45Δ | 3.01 | 235.2% | 15.9% | |||
| 50Δ | 3.20 | 231.1% | 14.4% | |||
| 55Δ | 3.40 | 226.9% | 12.9% | |||
| 60Δ | 3.59 | 222.7% | 11.4% | |||
| 65Δ | 3.78 | 218.5% | 9.8% | |||
| 70Δ | 3.98 | 214.3% | 8.3% | |||
| 75Δ | 2.40 | 163.5% | 4.5% | 4.17 | 210.1% | 6.8% |
| 80Δ | 2.27 | 171.0% | 3.5% | 4.36 | 205.9% | 5.2% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.95
- IV
- 508.5%
- B/E move
- 43.4%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.62
- IV
- 243.6%
- B/E move
- 19.0%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.81
- IV
- 239.4%
- B/E move
- 17.5%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.01
- IV
- 235.2%
- B/E move
- 15.9%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.20
- IV
- 231.1%
- B/E move
- 14.4%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.40
- IV
- 226.9%
- B/E move
- 12.9%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.59
- IV
- 222.7%
- B/E move
- 11.4%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.78
- IV
- 218.5%
- B/E move
- 9.8%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.98
- IV
- 214.3%
- B/E move
- 8.3%
75Δ
- Pseudo strike
- 2.40
- IV
- 163.5%
- B/E move
- 4.5%
- Pseudo strike
- 4.17
- IV
- 210.1%
- B/E move
- 6.8%
80Δ
- Pseudo strike
- 2.27
- IV
- 171.0%
- B/E move
- 3.5%
- Pseudo strike
- 4.36
- IV
- 205.9%
- B/E move
- 5.2%
Options history
Table
| Date | IV (%) |
|---|---|
| 124.75% | |
| 146.92% | |
| 119.79% | |
| 138.59% | |
| 129.73% | |
| 153.49% | |
| 116.77% | |
| 124.87% | |
| 167.02% |
Biotechnology
PBLS
Parabilis Medicines, Inc. (Ticker: PBLS) is an emerging company at the forefront of the telecommunications sector, dedicated to delivering innovative communication solutions…
More →PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States and…
More →PCVX
Vaxcyte, Inc., a pre-clinical biotech vaccine company, develops novel vaccines to prevent or treat infectious diseases globally. The company is headquartered in Foster City,…
More →PDSB
PDS Biotechnology Corporation, a clinical-phase biopharmaceutical company, is focused on developing multifunctional cancer immunotherapies. The company is headquartered in Florham…
More →PEPG
PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious neurological and…
More →PGEN
Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
More →